Alkermes Plc (ALKS.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|55||2011||Chairman of the Board, Chief Executive Officer|
|49||2011||Chief Financial Officer, Senior Vice President, Treasurer|
|2018||Chief Operating Officer|
|58||2017||Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary|
|57||2018||Executive Vice President - Science and Therapeutics|
- BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461
- BRIEF-Alkermes Says CEO's FY 2017 Total Compensation Was $9.4 Mln VS $9.6 Mln In FY 2016
- BRIEF-Alkermes CEO Says Does Not Believe Additional Trials Of Depression Drug Necessary
- FDA refuses to review Alkermes' depression treatment, seeks more trials
- UPDATE 3-FDA refuses to review Alkermes' depression treatment, seeks more trials